Compugen Sets March 2 Results Release and April 13 Needham Conference Presentation
Compugen said it will release fourth quarter and full year 2025 results on March 2, 2026, and present at the Needham Virtual Healthcare Conference on April 13. The company also outlined its Phase 1 and Phase 3 immuno-oncology pipeline programs.
Compugen Ltd. announced that it will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open, and that management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. The company also said management will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, from 8:45-9:25 AM ET.
A live webcast of the March 2 conference call will be available through the company's website, and a replay will be available following the live webcast. A live webcast of the April 13 conference presentation will be accessible on the Investor Relations section of the company's website, and a replay will also be available following the live event.
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform, Unigen™, to identify novel drug targets and biological pathways for developing cancer immunotherapies. The company has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development, and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies.
The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development, Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody, and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer.
Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.